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Abstract: Impairment of attention and memory in patients with Alzheimer’s disease (AD) 
is associated with signiﬁ  cantly lower levels of acetylcholine. Inhibition of the breakdown of 
acetylcholine by blocking the enzymes acetylcholinesterase and butyrylcholinesterase with 
rivastigmine improves this cholinergic depletion. Thus rivastigmine administration provides 
established, effective, long-term symptomatic treatment in AD and Parkinson’s disease (PD) 
patients with dementia. A sustained treatment with cholinesterase inhibitors in general may 
also induce a certain deterioration of ﬁ  ne motor behavior, which may play a crucial role in the 
treatment of PD patients with dementia. Recent studies show that this altered balance between 
dopamine and acetylcholine due to cholinesterase inhibition, with its possible negative impact on 
motion behaviour, does not present a major problem in clinical practice in AD patients and may 
be compensated for by modiﬁ  cation of dopaminergic substitution in PD patients with dementia. 
However, progression of neurodegeneration increases the vulnerability for psychosis in AD 
and PD patients with dementia in combination with dehydration and often requires additional 
application of neuroleptics. Since classical neuroleptics increase extrapyramidal symptoms, 
atypical neuroleptics are used. Out of these, quetiapine shows a distinct lower anticholinergic 
(muscarinergic) potency with beneﬁ  cial effects on cognition. This favors its use in combination 
with rivastigmine.
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Introduction
Alzheimer’s disease (AD) is the commonest cause of dementia affecting older 
people. Research advances have enabled a detailed understanding of the molecular 
pathogenesis of the hallmarks of the disease, ie, plaques, composed of amyloid beta, 
and tangles, composed of hyperphosphorylated tau. The neurodegenerative AD process 
is histopathologically characterized by nerve cell loss, extracellular deposits of beta 
amyloid protein, and intraneuronal formation of neuroﬁ  brillary tangles. These changes 
do not exclusively occur in the cerebral cortex but also in several subcortical nuclei. 
The nucleus basalis of Meynert is most severely affected. Its neurons are cholinergic 
and project into many cortical areas. Loss of these nerve cells results in a widespread 
reduction of the cholinergic activity in the cortex. Cholinergic depletion is associated 
with impairment of attention and memory; therefore the cholinergic deﬁ  cit in AD 
presumably contributes to some of the core symptoms. However, as knowledge 
increases so does also the appreciation for the pathogenic complexity of the disorder. 
Familial AD is a very rare autosomal dominant disease with early onset, caused by 
mutations in the amyloid precursor protein and presenilin genes, both linked to amyloid 
beta metabolism. By contrast with familial disease, sporadic AD is very common with 
more than 15 million people affected worldwide (Blount et al 2002; Cummings 2005; 
Alva and Potkin 2003). The cause of the sporadic form of the disease is unknown, Neuropsychiatric Disease and Treatment 2007:3(2) 212
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probably because the dementia and AD in particular is 
heterogeneous, caused by aging in concert with a complex 
interaction of both genetic and environmental risk factors 
(Blennow et al 2006).
The common mode of action of 
cholinesterase inhibitors (ChEI)
Pathological changes in AD involve cholinergic neuronal 
pathways that project from the basal forebrain to the cerebral 
cortex and hippocampus. These pathways are thought to 
be intricately involved in memory, attention, learning, 
and other cognitive processes. These are accomplished 
by decreased concentrations of acetylcholine, which are 
modulated by the enzyme cholinesterase. This enzyme is of 
neuronal origin and functions to metabolize acetylcholine 
at synapses throughout the nervous system. Cholinesterase 
breaks down acetylcholine, a neurotransmitter which assists 
in human memory and cognition processes. By inhibiting 
cholinesterase, more acetylcholine is available to the patient 
for memory and cognitive functioning. This is effective 
in treatment of AD, since acetylcholine is at signiﬁ  cantly 
lower levels in AD patients than in normally functioning 
people. These drugs block the enzyme that inactivates the 
transmitter in the synaptic cleft. It should be noted that 
ChEI are a symptomatic, not causal, treatment of AD. ChEI 
increase the concentration of acetylcholine in the brain. 
As AD progresses and cortical neurons are lost, levels of 
acetylcholinesterase progressively decline, while levels of 
butyrylcholinesterase increase. Butyrylcholinesterase 
can and does take over the function of metabolizing 
acetylcholine at the synapse, when acetylcholinesterase 
is lost, a phenomenon that has been demonstrated in an 
acetylcholinesterase knockout mouse model and which 
probably occurs in AD (Polinsky 1998). Rivastigmine, but 
not its competitors, inhibits both acetylcholinesterase and 
butyrylcholinesterase by covalently binding to active sites 
on these enzymes, blocking their function. Breaking of 
these covalent bonds is the ﬁ  rst and most important step in 
the degradation of rivastigmine, which is not metabolized 
in the liver (Greig et al 2002; Darvesh et al 2003; Eskander 
et al 2005).
Symptomatic drug treatment 
approaches
Since the introduction of the first ChEI in 1997, most 
clinicians and probably most patients would consider the 
cholinergic drugs donepezil, galantamine, and rivastigmine 
to be the ﬁ  rst-line pharmacotherapy for mild to moderate 
AD. These drugs have slightly different pharmacological 
properties, but they all work by inhibiting the breakdown of 
acetylcholine, an important neurotransmitter associated with 
memory, by blocking the enzyme acetylcholinesterase. The 
most that these drugs could achieve is to modify the clinical 
manifestations, in particular the cognitive impairment, of 
AD. Moreover there is accumulating evidence that they also 
improve additional affected domains of global functioning, 
such as activities of daily living or behavior (Cummings 
2000; Bonner and Peskind 2002; Clegg et al 2002).
Objective
Objective is to review the efﬁ  cacy of rivastigmine in the 
treatment of AD and to provide an outlook of its effect in the 
treatment of dementia in Parkinson’s disease (PD).
Essential clinical AD trials 
with rivastigmine
The safety and efﬁ  cacy of rivastigmine were investigated 
in several placebo-controlled investigations (see Table 1). 
Participants, all AD patients, were evaluated in terms 
of their cognitive performance using the Alzheimer’s 
Disease Assessment Scale (ADAS-cog) and the Clinician’s 
Interview Based Impression of Change (CIBIC-Plus). The 
ADAS-cog considers elements of memory, orientation, 
attention, reasoning, language, and praxis. Improvement in 
global functioning was measured by the CIBIC-Plus. This 
instrument of evaluation considers overall patient cognition, 
behaviour, and functioning. The patient population for these 
studies tried to reﬂ  ect a real world population, since most 
of the patients used concomitant medications to treat other 
conditions during the studies. In a 26-week, US study, patients 
were divided into three groups, each receiving 1–4 mg/day 
of rivastigmine, 6–12 mg/day of rivastigmine, or placebo. At 
the end of the treatment period, both ADAS-cog scores and 
CIBIC-Plus ratings for those treated in either dose-group of 
rivastigmine were signiﬁ  cantly superior to the scores of those 
who took placebo. Furthermore, the higher-dosage group 
had better ADAS-cog scores and CIBIC-Plus ratings than 
the lower-dosage group. Better scores in these assessments 
indicate greater improvement and less worsening in cognitive 
function (such as memory, recognition, ability to speak, 
and other symptoms of dementia) than the average placebo-
treated patient. In another 26-week, global study, patients 
were divided into similar groups. Results of this study also 
indicated that the 6–12 mg/day group showed signiﬁ  cantly Neuropsychiatric Disease and Treatment 2007:3(2) 213
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better ratings for CIBIC-Plus than placebo, and signiﬁ  cantly 
better scores on the ADAS-cog scale, compared with placebo 
and the 1–4 mg/day group. However, the 1–4 mg/day treatment 
group did not improve signiﬁ  cantly over placebo with 
either assessment tool. These trials and other clinical trials 
not reported in detail in this review provided evidence for the 
clinical efﬁ  cacy of rivastigmine in AD treatment (Spencer 
and Noble 1998; Rosler et al 1999; Tariot 2001; Wilkinson 
et al 2002; Ritchie et al 2004; van Dyck 2004; Wilkinson et 
al 2004; Takeda et al 2006).
Side-effects 
The most common side-effects of rivastigmine, as 
experienced by patients in clinical studies, were nausea, 
vomiting, anorexia, dyspepsia, asthenia, and weight loss. 
These effects were experienced with greater frequency earlier 
in the treatment. Therefore it is recommended taking the drug 
with a meal. Side-effects often settle down with time. 
Long-term administration 
of rivastigmine in the studies 
and in the real world
Limited data are available on the tolerability and effectiveness 
of ChEI therapy for periods up to 5 years. But all available 
data indicate that rivastigmine was well tolerated and 
efﬁ  cacious. There is some evidence that early therapy with 
rivastigmine may confer some beneﬁ  t in delaying long-
term progression of symptoms, as has been suggested by 
analysis of the combined 26 weeks of double-blind and ﬁ  rst 
26 weeks of open-label data. Throughout the initial 26-week 
double-blind part, patients receiving placebo steadily 
deteriorated, while those treated with high-dose rivastigmine 
were able to maintain their baseline level of performance on 
the ADAS-Cog. This approximated a delayed-start design for 
the open-label portion, which demonstrated that patients who 
started rivastigmine late never “caught up” with patients who 
had been on high-dose rivastigmine from the beginning of 
the trial. This suggests a disease-progression-delaying effect 
of the drug, which may allow this population to maintain 
their autonomy for a longer period of time. However, it is 
important to emphasize the limitations of these data. They are 
retrospective, the sample was small, there were signiﬁ  cant 
numbers of drop-outs, and the availability of free rivastigmine 
ceased with FDA approval that occurred near to the end of 
the study (Belle et al 2004; Farlow and Lilly 2005). More 
recent studies have demonstrated that efﬁ  cacy and patterns 
of ChEI use are more complex than previously appreciated. 
Data now strongly support efﬁ  cacy for ChEI across the 
progressive stages of AD. Using combined data from three 
randomized, placebo-controlled rivastigmine trials, Kurz 
et al found that rivastigmine maintained ADAS-Cog scores at 
or above placebo levels across mild, moderate, and severe 
stages, and the beneﬁ  ts of drug therapy were increasingly 
apparent at more advanced stages as the rate of decline 
accelerated in the placebo condition (Frankfort et al 2005; 
Kurz et al 2004). One study on rivastigmine involved 235 
patients who were randomized to the study drug or placebo, 
187 of whom subsequently crossed over to open-label 
treatment with rivastigmine (Farlow et al 2001). The study 
found that placebo patients who progressed faster during the 
Table 1 Essential published rivastigmine trials in AD
  Study design  Study duration  Intervention and number of   Relevant objectives
     randomized  patients
Corey-Bloom 1998  RCT, parallel, double-  26 weeks  1. Rivastigmine 1–4 mg: n = 233  ADAS-cog, CIBIC-plus, 
  blind, multicenter    2. Rivastigmine 6–12: n = 231  PDS
      3. Placebo: n = 235  Adverse events
Forette 1999  RCT, parallel, double-  18 weeks  1. Rivastigmine bid (6–12 mg/d): n = 45  ADAS-cog, CIBIC-plus, 
  blind, multicenter    2. Rivastigmine tid (6–12 mg/d): n = 45  NOSGER
  Phase II study    3. Placebo: n = 24  Adverse events
Rösler 1999  RCT, parallel, double-  26 weeks  1. Rivastigmine 1–4 mg: n = 243  ADAS-cog, CIBIC-plus, 
  blind, multicenter    2. Rivastigmine 6–12 mg: n = 243  PDS
      3. Placebo: n = 239  Adverse events
Bullock 2005  RCT, parallel, double-  24 months  1. Rivastigmine 3–12 mg: n = 498  SIB
  blind, multicenter    2. Donepezil 5–10 mg: n = 500  ADCS-ADL, GDS,NPI
       Adverse  events
Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment Scale; CIBIC-Plus, Clinician’s Interview Based Impression of Change; GDS, Global Deterioration Scale; NPI, 
neuropsychiatric inventory; NOSGER, Nurses Observations Scale for Geriatric Patients; PDS, Progressive Deterioration Scale; RCT, randomized controlled trial; b(t)id, 2 (3) 
times in one day; n, number of treated individuals; SIB, severe impairment battery.Neuropsychiatric Disease and Treatment 2007:3(2) 214
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double-blind phase responded more robustly to subsequent 
rivastigmine treatment (according to the ADAS-Cog and 
Progressive Deterioration Scale [PDS] scores). Other studies 
have found that factors besides drug safety and efﬁ  cacy 
inﬂ  uence patterns of ChEI use. Gill et al, in comparing 6400 
new users of donepezil versus 3400 subjects enrolled in 10 
randomized, controlled trials, found that 51%–78% would 
not have been eligible to participate in randomized trials 
because of advanced age, medical additional morbidities, or 
residence in long-term care. In addition, 28% of new users 
had stopped taking donepezil by 8 months of treatment, with 
discontinuation more likely in patients with greater additional 
morbidities (Gill et al 2004). This suggests that physicians 
may not be conﬁ  dent in prescribing ChEI for patients who 
differ from typical participants of randomized, controlled 
trials, and that more data are needed on clinical outcomes in 
these “real world” patient populations. With rivastigmine it is 
obvious that in comparison with the ﬁ  xed-dose regimen with 
donepezil, a more ﬂ  exible-dose rivastigmine titration regime 
enables improved drug tolerability through slower escalation 
of dosing with individualized titration. Caregivers and social 
demographic factors also play an important role in decisions 
about ChEI use. Belle and colleagues examined predictors 
of use by patients with dementia whose caregivers were 
enrolled in the multi-site caregiver intervention Resources 
for Enhancing Alzheimer’s Caregiver Health (REACH) 
trial (Belle et al 2004). Only 31% of care recipients used a 
cognitive enhancer at baseline; use was predicted by race 
(white), higher levels of education, less severe dementia, care 
giving time, and being a spouse rather than a parent of the 
caregiver. Over the course of the study, a higher proportion 
of patients stopped taking ChEI than started the treatment. 
This study suggests that educating caregivers about the 
benefits of long-term treatment could improve rates of 
sustained use required for optimal outcomes. The long-term 
effects of rivastigmine have been examined in an open-label 
extension of the placebo-controlled trials. Regardless of the 
treatment arm to which patients had been allocated until 
week 26, they were restarted on rivastigmine and titrated 
upward to the maximum tolerated dose, but not exceeding 
12 mg/day. Patients already on a high dose in the double-
blind study phase remained above their cognitive baseline 
level until week 40 and slowly declined thereafter. Patients 
who had received a low dose of rivastigmine or placebo in 
the double-blind study phase showed a rapid improvement 
when restarted on rivastigmine but did not catch up with the 
high-dose group. This implies that for maximum beneﬁ  t, 
treatment should be started as early as possible. After week 
40 cognitive ability slowly declined also in the two latter 
groups. Importantly, all three groups performed better on the 
ADAS-cog at 1 year than the placebo group had performed 
at 6 months. Apparently patients beneﬁ  t from treatment even 
after the 40-week period of cognitive stabilization (Farlow 
et al 2000; Darreh-Shori et al 2002; Erkinjuntti et al 2002; 
Farlow 2002; Farlow et al 2003; Darreh-Shori et al 2004; 
Farlow and Lilly 2005). To date, there is only one relevant 
head-to-head trial on the efﬁ  cacy of ChEI, rivastigmine, 
and donepezil. This study describes similar efﬁ  cacy of 
rivastigmine and donepezil on cognition and behaviour, 
and greater beneﬁ  t in activities of daily living and global 
functioning in the rivastigmine arm is concluded (Bullock 
et al 2005; Winblad et al 2006).
Essentials points to sustained
ChEI treatment 
Sustained treatment requires consideration of individual 
differences between patients, the magnitude of therapeutic 
response, the likelihood of response to a speciﬁ  c drug, 
and tolerance for dose escalation. Active anticipation, 
management, and monitoring are required for additional 
morbidities such as heart or lung disease, urinary incontinence, 
and complications of dementia (eg, dehydration, hypotension, 
obstipation, undernutrition, falls). In addition, an attitude 
of realistic optimism about management and a perspective 
rooted in principles of chronic disease management are 
key attributes of physicians and families caring for patients 
with dementia. A comprehensive, long-range, collaborative 
dementia care partnership, with a focus on the goals of 
slowing decline and prolonging quality of life, is the means 
by which overall outcomes can be optimized (Giacobini 
2000; Frankfort et al 2005, 2006). 
Novel delivery approaches of 
rivastigmine – the IDEAL study 
Transdermal drug delivery systems (usually by drug 
“patches”) are designed to provide controlled, continuous 
delivery of drugs through the skin, thereby maintaining more 
consistent blood levels of the drug. Patches also minimize 
processing of the drug in the liver, stomach, and intestines. 
These advantages may make it easier to achieve therapeutic 
levels of the drug in the bloodstream with lower dosages 
than pills, thereby possibly reducing side-effects. Since AD 
initially affects memory, reasoning, and decision-making 
abilities, it can be a problem for people with the disease to Neuropsychiatric Disease and Treatment 2007:3(2) 215
Rivastigmine in AD 
take drugs on a regular schedule. As the disease advances, 
people may not know what drugs are for or even what they 
are. With further advance of the disease, sometimes the 
ability to swallow is affected. Transdermal drug delivery has 
the potential to eliminate issues such as forgetting to take the 
drug or to take it at the right time, and also ease challenges 
associated with getting the person with Alzheimer’s to take 
or swallow a pill. It also provides visual reassurance for 
the caregiver that the medication has been taken. At the 
same time, possible skin irritation and the presence of a 
new or unknown object on their body may be confusing or 
annoying to the person with Alzheimer’s, so a skin patch 
may not work for everyone (Muhlack et al 2006; Priano 
et al 2006). The IDEAL (Investigation of TransDermal 
Exelon in ALzheimer’s disease) was a 24-week, multi-
center, randomized, double-blind, placebo- and active-
controlled evaluation of once-daily rivastigmine patches 
versus twice-daily capsules in 1195 patients with moderate 
stage Alzheimer’s. Patients were 50–85 years of age. Tested 
patch sizes were 10 cm2 (9.5 mg/24 hours) or 20 cm2 (17.4 
mg/24 hours), and capsules were 6 mg twice-daily. Primary 
outcome measures were the ADAS-cog and Alzheimer’s 
Disease Cooperative Study-Clinical Global Impression of 
Change (ADCS-CGIC). The rivastigmine patch showed 
statistically signiﬁ  cant beneﬁ  ts versus placebo on both of 
these measures and the ability to perform activities of daily 
living. The recommended target dose 10 cm2 patch showed 
similar efﬁ  cacy to the highest doses of rivastigmine capsules 
with three times fewer reports of nausea (7.2% vs 23.1%) 
and vomiting (6.2% vs 17.0%), which are well-known 
side-effects of ChEI. The 20 cm2 patch showed improved 
cognitive scores versus capsules and similar tolerability 
to capsules. Local skin tolerability was good. Abnormal 
redness of the skin was present at moderate or severe levels 
in only 7.6% and 6.2% of patients receiving 10 and 20 cm2 
patches, respectively. A questionnaire was given to more than 
1000 caregivers whose loved ones were AD patients. The 
caregivers signiﬁ  cantly preferred the patch to capsules for 
ease of following the treatment schedule, overall ease of use, 
and less interference with daily life (Winblad et al 2006). 
Rivastigmine and its impact 
on motor behavior in AD,
and PD, patients
There are reports on deterioration of ﬁ  ne motor behavior 
during treatment with ChEI, but concomitant application of 
typical and atypical neuroleptics confounded study outcomes 
or case reports in AD, or PD, patients with dementia (Heinze 
et al 2002; Richard et al 2002; Werber and Rabey 2001; 
Bohnen et al 2004). A further drawback of these reports was 
a missing compliance control of AD individuals due to oral 
ChEI administration with their sometimes nausea-inducing 
effects. One placebo-controlled trial showed a discrete, non-
signiﬁ  cant improvement of smoothness of hand movements 
following oral intake of donepezil during a 12-week interval 
with the use of a standardized handwriting paradigm (Hegerl 
et al 2003). This positive effect was independent of changes 
in cognitive function, and conﬁ  rmed outcomes of a study 
suggesting normalization of disturbances in the motor cortex 
of patients with AD treated with donepezil (Liepert et al 
2001). However, writing with the non-dominant hand in 
particular is rather complex and demands a certain cognitive 
load, and moreover hand dominance may inﬂ  uence outcomes 
of assessment of motor activity (Van Hilten et al 1993). 
Therefore more simple instrumental motor tests are also 
suitable, to address this issue on impact of cholinesterase 
inhibition on motion. A standardized peg insertion procedure 
is such a tool. It requires conduction of a complex motion 
series. This instrumental tool did not show a signiﬁ  cant change 
of outcomes during an open label treatment with donepezil 
during an interval of 12 weeks, whereas there was a non-
signiﬁ  cant trend for improvement of simple motions apparent 
within a ﬁ  nger tapping paradigm (Bohnen et al 2004). A 
further trial that investigated the impact of transdermal 
rivastigmine administration on motor performance with an 
altered standardized peg insertion paradigm showed that 
patients with predominant cholinergic neurodegeneration 
need longer for performance of the peg insertion paradigm 
in comparison with controls. Thus this study conﬁ  rms a 
deterioration in carrying out of complex motion series in 
neurodegenerative processes, because this was also shown 
in disorders with preponderant functional basal ganglia 
disturbances, ie, Huntington’s disease or PD (Müller et al 
2000; Saft et al 2003, 2004). This trial also conﬁ  rmed that 
assessment of co-ordinated movements with the non-
dominant hand better reﬂ  ects disturbances of ﬁ  ne motor 
behavior during neurodegeneration probably due to regular 
training and use (Müller et al 2000, 2003b; Pal et al 2001; van 
Vugt et al 2001; Saft et al 2003, 2004). An improved brain 
plasticity of the dominant brain hemisphere with secondary 
better compensation of motor deﬁ  cits may additionally 
be responsible for the inferior sensitivity of the applied 
instrumental paradigm to reﬂ  ect motor disturbances of the 
upper limb during a neurodegenerative process (Van Hilten Neuropsychiatric Disease and Treatment 2007:3(2) 216
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et al 1993; Müller et al 2000, 2003b; van Vugt et al 2001; 
Ioffe 2004; Saft et al 2004). The impaired motor function 
found supports the concept of subclinical motor cortex 
disinhibition during chronic cholinergic neurodegeneration. 
This results in functional motor disturbances in AD and 
may be aggravated by the cholinergic dysfunction and the 
resulting frontal dysbalance of dopaminergic and cholinergic 
neurotransmission (Liepert et al 2001; Jefferson et al 2002; 
Di Lazarro et al 2004). However, further future trials with 
enrolment of more participants, serial evaluation, and better 
clinical characterization of the cognitive deﬁ  cit are needed 
to address this issue in dementia-related processes. However, 
no deterioration of complex motion performance was found 
during this transdermal rivastigmine application in AD 
(Muhlack et al 2006). This ﬁ  nding is of interest, since there is 
a controversial debate on onset of extrapyramidal symptoms 
during cholinesterase inhibition in AD patients or patients 
with parkinsonism in dementia with lewy bodies (Heinze 
et al 2002; Richard et al 2002; Hegerl et al 2003; Di Lazarro 
et al 2004). One may conclude that rivastigmine does not 
cause an impairment of complex movement performance 
with its demand for additional various forms of complex 
information processing with visual, cognitive, and sensory 
inputs (Pal et al 2001; Müller et al 2003a, 2003b). This may 
be due to the pharmacological proﬁ  le of rivastigmine with 
its selective inhibition of the G 1 cholinesterase isoform, 
which is predominantly located in cortical and hippocampal 
regions and may therefore favor the use of rivastigmine in 
PD patients with dementia (Weinstock 1999).
Symptomatic treatment of 
cognitive deﬁ  cits in PD patients 
with dementia 
ChEI improve dementia in PD patients, which results from 
a distinct cholinergic deﬁ  cit (Tiraboschi et al 2000). The 
multi-center EXPRESS study compared the efﬁ  cacy of 
rivastigmine, an inhibitor of both acetylcholinesterase and 
butyrylcholinesterase, with placebo. In this trial, rivastigmine 
produced a moderate but signiﬁ  cant improvement in PD 
patients with dementia. The mean rivastigmine dosage was 
8.6 mg at the end of the dose-escalation phase and remained 
stable throughout the maintenance phase. Predominant cho-
linergic adverse effects, ie, nausea or vomiting, occurred. 
The rivastigmine-treated participants mostly characterized 
these side-effects as mild to moderate and accordingly the 
rate of premature withdrawal was relatively low. These trials 
supported the accumulating evidence that ChEI also improve 
symptoms of dementia in PD patients and allied conditions 
(Emre 2004), which remained stable in the open extension 
phase of this trial (Poewe et al 2006). Predominant open-
label, earlier, smaller trials with donepezil and rivastigmine 
also demonstrated an improvement of cognitive function 
in various kinds of patients with impairment of motor and 
cognitive function (Werber and Rabey 2001; Giladi et al 
2003; Leroi et al 2004). The controversial debate on onset 
or aggravation of extrapyramidal symptoms during cholin-
esterase inhibition in PD patients is not ﬁ  nally answered by 
the EXPRESS study, since this trial allowed a modiﬁ  cation 
of the dopaminergic substitution as a minor adverse event. 
Symptomatic treatment of 
psychosis in AD, and PD, patients 
with dementia
There is a relationship between progression of neurodegeneration, 
cognitive deﬁ  cits, and psychosis in AD, and PD, patients 
with dementia (Merims et al 2004). Vivid dreams, 
fear, predominant optic illusions, anxiety, paranoia, 
hallucinations, and sleep loss are initial clinical signs. 
Each antiparkinsonian drug may support onset of 
psychosis in particular in combination with dehydration. 
Since classical neuroleptics increase extrapyramidal 
symptoms, atypical neuroleptics are used for treatment 
of psychotic symptoms in PD. The atypical antipsychotic 
agent clozapine is well tested in clinical trials. It shows 
additional sedative and tremor-reducing components 
and prevents recurrence of psychosis (Parkinson Study 
Group 1999; Factor et al 2001). However, rare induction 
of leucopenia and transient low fever limit its use. The 
metabolism of clozapine via CYP1A2, CYP3A4, CYP2C19, 
and CYP2D6 may increase levels of compounds, which 
share these metabolic pathways. Quetiapine has structural 
similarities to clozapine and the same antipsychotic 
efﬁ  cacy. This drug has a distinct lower anticholinergic 
(muscarinergic) potency in comparison with clozapine 
(Matheson and Lamb 2000). Therefore open trials with 
quetiapine reported improved cognition in PD patients. 
This suggests that quetiapine is more suitable for long-
term use than clozapine in neurodegenerative disorders, 
ie, AD or PD, or both (Juncos et al 2004; Morgante et al 
2004).
Conclusion
Rivastigmine provides a distinct beneﬁ  t for AD, and PD, 
patients with dementia. There is some evidence that a Neuropsychiatric Disease and Treatment 2007:3(2) 217
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clinically relevant deterioration of motion behavior does 
not occur during sustained rivastigmine application in AD 
patients. From this point of view rivastigmine is also suitable 
for the treatment of PD patients with dementia.
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